Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 449Carcinoma, Non-Small-Cell Lung 372Neoplasms 349Prostatic Neoplasms 285Colorectal Neoplasms 273Multiple Myeloma 211Lung Neoplasms 201Neoplasm Metastasis 185Leukemia, Myeloid, Acute 163Ovarian Neoplasms 159Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 140Melanoma 131Recurrence 108Glioblastoma 105Head and Neck Neoplasms 103Carcinoma, Renal Cell 103Endometrial Neoplasms 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Lymphoma, Non-Hodgkin 95Stomach Neoplasms 94Carcinoma, Hepatocellular 94Lymphoma 93Triple Negative Breast Neoplasms 92Brain Neoplasms 90Uterine Cervical Neoplasms 86Lymphoma, Large B-Cell, Diffuse 81Glioma 79Urinary Bladder Neoplasms 78Sarcoma 78

Interventions

rasburicase 1Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Tumor Lysis Syndrome × 30 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡